Abstract
Objective: On account of several complications and adverse effects associated with the use of conventional chemotherapeutic regimen, the advanced drug-targeted therapies have gained the remarkable attention of the researchers due to their fabulous pharmaceutical and therapeutic advantages. The present study was designed with the aim to synthesize manganese ferrite nanoparticles (MnFe2O4 NPs) and folic acid-conjugated doxorubicin (DOX)-loaded manganese ferrite bovine serum albumin NPs (FA-BSA-DOX-MnFe2O4 NPs) using desolvation cross-linking method.Methods: Having assessed their physicochemical characteristics, the prepared NPs were evaluated for hem compatibility, photo-mediated cytotoxicity, and anti-cancer potential against human cervical carcinoma cell line (HeLa) using a range of in vitro assays which include hemolysis assay, sulforhodamine B (SRB) and MTT assays.Results: Spectroscopic characterization revealed that MnFe2O4 NPs were spherical with an average size diameter of approx. 15 nm and a band gap of 1.4 eV. Another remarkable feature of FA-BSA-DOX conjugated MnFe2O4 NPs was high entrapment efficiency (approx. 95%). MTT assay demonstrated that MnFe2O4 NPs revealed potential photosensitizing ability upon exposure to sunlight. FA-BSA-DOX conjugated MnFe2O4 NPs showed promising cytotoxicity against human cervical epithelial malignant carcinoma cell line (HeLa). Interestingly, the cytotoxicity of these NPs was gradually increased with time of exposure to sunlight.Conclusion: These findings suggested that FA-BSA-DOX conjugated MnFe2O4NPs exhibit promising photosensitizing and anticancer potential against human cervical carcinoma and thus can be considered as an alternative targeted therapy against human cervical cancer.
Highlights
Cancer tends to remain the major cause of fatalities worldwide
The recent leap is the combined onco-therapeutic technique which is employed for targeting cancers through multiple mechanisms, for instance, a combination of targeted drug delivery and photodynamic therapy (PDT)
1,2-hexadecanediol (90%), oleylamine (98%), oleic acid (99%), isopropanol (99.7%),folic acid (97%), doxorubicin hydrochloride (98.0%), bovine serum albumin(Mw 66,000), glutaraldehyde, Nhydroxysuccinimide (NHS, 98%), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDAC), citric acid were purchased from Sigma-Aldrich (USA); methylene blue from Merck and co
Summary
Cancer tends to remain the major cause of fatalities worldwide. For decades, scientists have been hoping to find a promising cure for the said menace. The recent leap is the combined onco-therapeutic technique which is employed for targeting cancers through multiple mechanisms, for instance, a combination of targeted drug delivery and photodynamic therapy (PDT). This strategy tends to target various prime signal transduction pathways for the amplification of fused therapeutic efficacy [3]. This combination may give rise to synergistic effects thereby, leading to a reduction of the dose of the drug for enhanced feasibility, thereby undermining side effects usually associated with chemotherapeutic agents like doxorubicin (DOX) [4]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Pharmacy and Pharmaceutical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
